Sensory Cloud’s SC0023 Shows Promise in Refractory Chronic Cough Phase II Trial

Sensory Cloud reported encouraging results from its Phase II REACH trial of SC0023 at King Saud University Medical City in Saudi Arabia, demonstrating a reduction in cough rates for patients with refractory chronic cough (RCC). SC0023 is a therapeutic aerosol containing ions naturally found in human airways. The trial’s crossover design revealed therapeutic period effects, limiting primary efficacy analysis to the initial dosing period. Post hoc analysis showed a 34% placebo-adjusted cough rate reduction among six participants, while monitoring via Hyfe Cough Monitor indicated persistent cough suppression lasting several weeks after dosing, despite SC0023’s three-hour clearance time. Investigators suggest this sustained effect may relate to treatment decompression and down-regulation of mechano-sensitive ion channels. Trial lead, highlighted the global burden of chronic cough, affecting around 10% of adults, while CEO David Edwards noted consistent treatment efficacy between Riyadh and London, suggesting indoor arid-air environments influence outcomes. Based on these findings, Sensory Cloud will conduct a multi-site Phase II trial in Belfast and London.

27-09-2025